Comparative Pharmacology
Head-to-head clinical analysis: OMEPRAZOLE versus YOSPRALA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMEPRAZOLE versus YOSPRALA.
OMEPRAZOLE vs YOSPRALA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
Yosprala is a combination of aspirin (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet aggregation) and omeprazole (a proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme in gastric parietal cells).
20-40 mg orally once daily before a meal for 4-8 weeks.
YOSPRALA (esomeprazole magnesium and naproxen) is available as delayed-release tablets containing 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole. The typical adult dose is one tablet twice daily, swallowed whole with liquid, at least 30 minutes before meals.
None Documented
None Documented
Clinical Note
moderateEsomeprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Esomeprazole."
Clinical Note
moderateOmeprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Omeprazole."
Clinical Note
moderateEsomeprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole."
Clinical Note
moderateTerminal elimination half-life is approximately 0.5–1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts much longer due to irreversible binding to the proton pump. The half-life is prolonged in patients with hepatic impairment (up to 3–4 hours in cirrhosis) and in CYP2C19 poor metabolizers (up to 2–3 hours).
Naproxen: terminal elimination half-life is approximately 14 hours (range 12–17 hours), allowing twice-daily dosing. Esomeprazole: terminal half-life is approximately 1.2–1.5 hours after single dose, increasing to ~1.5–2.5 hours with repeated dosing due to saturation of CYP2C19. Clinical context: naproxen's half-life supports sustained analgesic/anti-inflammatory effect; esomeprazole's shorter half-life requires daily dosing for acid suppression.
Approximately 77% of a dose is excreted in urine (as metabolites, including hydroxyomeprazole and the corresponding carboxylic acid and sulfone derivatives), and about 18% is eliminated in feces via biliary excretion. Less than 1% of the parent drug is excreted unchanged in urine.
YOSPRALA (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is primarily excreted in urine as unchanged drug (approximately 60%) and as glucuronide conjugates (approximately 30%). Esomeprazole is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder via metabolites.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Omeprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole."